Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 21, 2014; 20(27): 8783-8789
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8783
Published online Jul 21, 2014. doi: 10.3748/wjg.v20.i27.8783
Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: A review of the literature
Rosy Wang, Rupert W Leong, Gastroenterology and Liver Services, Concord Hospital, Sydney, Concord NSW 2139, Australia
Author contributions: Wang R contributed to this work; Leong RW designed the research; Wang R performed the literature review and analysed the data; Wang R and Leong RW wrote the paper.
Supported by Career Development Fellowship of the National Health and Medical Research Council of Australia, to Leong RW
Correspondence to: Rupert W Leong, Associate Professor, Gastroenterology and Liver Services, Concord Hospital, Level 1 West, Hospital Rd, Sydney, Concord NSW 2139, Australia. rupertleong@outlook.com
Telephone: +61-2-9767 6111 Fax: +61-2-9767 6767
Received: October 13, 2013
Revised: January 21, 2014
Accepted: April 5, 2014
Published online: July 21, 2014
Revised: January 21, 2014
Accepted: April 5, 2014
Published online: July 21, 2014
Core Tip
Core tip: The widely accepted risk factors for malignant transformation in inflammatory bowel disease (IBD) are disease duration and extent of inflammation. Since first proposed in 1992, one increasingly recognised independent risk factor for colorectal cancer development in IBD patients is concomitant primary sclerosing cholangitis.